Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00213980 · ClinicalTrials.gov registry record · Phase 2
Bone Mineral Density Effects of Zoledronate in Postmenopausal Women With Breast Cancer
A Phase 2 study, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 2
- Development phase
- 68
- Enrollment target
NCT00213980 is a Phase 2 study that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 68 participants.
The verdict
NCT00213980, a Phase 2 study, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 68 participants
- Enrollment target
Study Summary
This is a two arm, double-blind randomized study looking at the effect of zoledronate, a bisphosphonate, on the bone mineral density (BMD) of postmenopausal women with breast cancer.
Interventions
- DRUG Zoledronate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2000-01 |
| Est. Completion | 2008-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00213980
The ClinicalTrials.gov registry entry for NCT00213980 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Zoledronate is the first listed.
NCT00213980 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00213980 about?
NCT00213980 is a clinical study titled "Bone Mineral Density Effects of Zoledronate in Postmenopausal Women With Breast Cancer". This is a two arm, double-blind randomized study looking at the effect of zoledronate, a bisphosphonate, on the bone mineral density (BMD) of postmenopausal women with breast cancer.
What is the current status of trial NCT00213980?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 68 participants. The study started on 2000-01. Estimated completion is 2008-04.
What interventions are being tested in trial NCT00213980?
The interventions under investigation include: Zoledronate (DRUG).
Who is sponsoring clinical trial NCT00213980?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.